Idenix May Drop Delayed Hepatitis C Drug for New Versions

Idenix Pharmaceuticals, a developer of hepatitis C drugs, may shelve experimental treatments currently on hold by U.S. regulators and focus on different versions, CEO Ron Renaud said.
Bloomberg